These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8679057)

  • 1. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
    Kaufer DI; Cummings JL; Christine D
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
    Kaufer D; Cummings JL; Christine D
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):55-63. PubMed ID: 9547467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.
    Hayashi Y; Ishida Y; Inoue T; Udagawa M; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Sameshima T; Kawahara T; Goto I; Shudo K; Kurayama S; Nakamura J; Okahara K; Mitsuyama Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):541-5. PubMed ID: 20184936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.
    Matsui T; Nakaaki S; Murata Y; Sato J; Shinagawa Y; Tatsumi H; Furukawa TA
    Dement Geriatr Cogn Disord; 2006; 21(3):182-91. PubMed ID: 16401890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of tacrine.
    Kurz A
    J Neural Transm Suppl; 1998; 54():295-9. PubMed ID: 9850938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
    Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
    JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.
    Ahlin A; Junthé T; Hassan M; Nybäck H
    Int Psychogeriatr; 1995; 7(1):75-83. PubMed ID: 7579023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychiatric assessment of Alzheimer's disease and related dementias.
    Cummings JL; McPherson S
    Aging (Milano); 2001 Jun; 13(3):240-6. PubMed ID: 11444257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.